Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine Who Have Previously Failed 1 or More Migraine Preventive Treatments.

NCT03912337 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03912337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03912337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine Who Have Previously Failed 1 or More Migraine Preventive Treatments.
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Terminated
Start date
December 4, 2019
Completion date
July 28, 2021
Enrollment
29 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

migraine